EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Potent P2Y12 Inhibitor Monotherapy for Acute Coronary Syndrome

Sung-Jin Hong, Byeong-Keuk Kim

Circulation Journal · 25.02.2025 · 89 (3) · 272-280

DOI: 10.1253/circj.cj-23-0750 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Circulation Journal, erschienen am 25.02.2025. Verfasst von Sung-Jin Hong und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine. Hauptthemen laut MEDLINE: Acute Coronary Syndrome, Purinergic P2Y Receptor Antagonists, Platelet Aggregation Inhibitors. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 60 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dual antiplatelet therapy (DAPT), consisting of aspirin and a P2Y12inhibitor, has been the principal antiplatelet therapy after drug-eluting stent (DES) implantation in patients with acute coronary syndrome (ACS) and chronic coronary disease. Particularly in patients with ACS, which presents a higher ischemic risk than chronic coronary artery disease, DAPT for up to 12 months is the recommended standard treatment. However, to decrease bleeding events related to the potency of P2Y12inhibitors and a prolonged duration of DAPT, recent studies have suggested P2Y12inhibitor monotherapy after short-term DAPT (1-3 months), which decreased the bleeding risk without an increased ischemic risk. In this article, we discuss the evidence related to the efficacy of a P2Y12inhibitor as single-antiplatelet therapy after short-term DAPT compared with standard DAPT, with a focus on patients with ACS treated with DES.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Acute Coronary SyndromePurinergic P2Y Receptor AntagonistsPlatelet Aggregation InhibitorsHumansDrug-Eluting StentsHemorrhageDual Anti-Platelet TherapyAspirinPercutaneous Coronary Intervention

Stichwörter der Autor:innen

Acute coronary syndromeAntiplatelet therapyDrug-eluting stentPercutaneous coronary intervention

Substanzen

Purinergic P2Y Receptor AntagonistsPlatelet Aggregation InhibitorsAspirin

Autor:innen und Institutionen

  • Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine.

Zitieren

APA

Hong, S. J., & Kim, B. K. (2025). Potent P2Y12 Inhibitor Monotherapy for Acute Coronary Syndrome. Circulation Journal, 89(3), 272-280. https://doi.org/10.1253/circj.cj-23-0750

Vancouver

Hong SJ, Kim BK. Potent P2Y12 Inhibitor Monotherapy for Acute Coronary Syndrome. Circulation Journal. 2025;89(3):272-280. doi:10.1253/circj.cj-23-0750

BibTeX
@article{Hong2025,
  author = {Hong, Sung-Jin and Kim, Byeong-Keuk},
  title = {Potent P2Y12 Inhibitor Monotherapy for Acute Coronary Syndrome},
  journal = {Circulation Journal},
  year = {2025},
  volume = {89},
  number = {3},
  pages = {272--280},
  doi = {10.1253/circj.cj-23-0750}
}
Kostenlos starten →